Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Erritzoe

Showing results (61-70 of 143) with videos related to

Pageof 15
Sort By:
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 1, 2025
Dissociable effects of LSD and MDMA on striato-cortical connectivity in healthy subjectsNatalie Ertl, Imran Ashraf, Lisa Azizi, et al.
Frontiers in Psychiatry|July 10, 2024
Study protocol for "Psilocybin in patients with fibromyalgia: brain biomarkers of action"Julia Bornemann, James B Close, Kirran Ahmad, et al.
Psychoneuroendocrinology|April 2, 2010
Endogenous plasma estradiol in healthy men is positively correlated with cerebral cortical serotonin 2A receptor bindingVibe G Frokjaer, David Erritzoe, Anders Juul, et al.
Neuropharmacology|May 2, 2012
The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)C]Ro15-4513 positron emission tomography studyMaria Andreina Mendez, Jamie Horder, Jim Myers, et al.
The International Journal of Neuropsychopharmacology|February 15, 2014
In abstinent MDMA users the cortisol awakening response is off-set but associated with prefrontal serotonin transporter binding as in non-usersVibe Gedsoe Frokjaer, David Erritzoe, Klaus Kähler Holst, et al.
Bjpsych Open|September 6, 2022
Effects of psilocybin versus escitalopram on rumination and thought suppression in depressionTommaso Barba, Sarah Buehler, Hannes Kettner, et al.
Neuroscience Insights|October 10, 2024
Neuroimaging and the Investigation of Drug-Drug Interactions Involving PsychedelicsMatthew B Wall, Rebecca Harding, Natalie Ertl, et al.
Scientific Reports|August 22, 2023
Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiencesRichard J Zeifman, Hannes Kettner, Broc A Pagni, et al.
Annals of the New York Academy of Sciences|July 21, 2025
Perturbing whole-brain models of brain hierarchy: An application for depression following pharmacological treatmentMarcel Socoró-Garrigosa, Yonatan Sanz Perl, Morten L Kringelbach, et al.
Psychiatry Research|July 31, 2023
Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysisOtto Simonsson, Per Carlbring, Robin Carhart-Harris, et al.
Pageof 15

Showing results (61-70 of 143) with videos related to

Sort By:
Pageof 15
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 1, 2025
Dissociable effects of LSD and MDMA on striato-cortical connectivity in healthy subjectsNatalie Ertl, Imran Ashraf, Lisa Azizi, et al.
Frontiers in Psychiatry|July 10, 2024
Study protocol for "Psilocybin in patients with fibromyalgia: brain biomarkers of action"Julia Bornemann, James B Close, Kirran Ahmad, et al.
Psychoneuroendocrinology|April 2, 2010
Endogenous plasma estradiol in healthy men is positively correlated with cerebral cortical serotonin 2A receptor bindingVibe G Frokjaer, David Erritzoe, Anders Juul, et al.
Neuropharmacology|May 2, 2012
The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)C]Ro15-4513 positron emission tomography studyMaria Andreina Mendez, Jamie Horder, Jim Myers, et al.
The International Journal of Neuropsychopharmacology|February 15, 2014
In abstinent MDMA users the cortisol awakening response is off-set but associated with prefrontal serotonin transporter binding as in non-usersVibe Gedsoe Frokjaer, David Erritzoe, Klaus Kähler Holst, et al.
Bjpsych Open|September 6, 2022
Effects of psilocybin versus escitalopram on rumination and thought suppression in depressionTommaso Barba, Sarah Buehler, Hannes Kettner, et al.
Neuroscience Insights|October 10, 2024
Neuroimaging and the Investigation of Drug-Drug Interactions Involving PsychedelicsMatthew B Wall, Rebecca Harding, Natalie Ertl, et al.
Scientific Reports|August 22, 2023
Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiencesRichard J Zeifman, Hannes Kettner, Broc A Pagni, et al.
Annals of the New York Academy of Sciences|July 21, 2025
Perturbing whole-brain models of brain hierarchy: An application for depression following pharmacological treatmentMarcel Socoró-Garrigosa, Yonatan Sanz Perl, Morten L Kringelbach, et al.
Psychiatry Research|July 31, 2023
Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysisOtto Simonsson, Per Carlbring, Robin Carhart-Harris, et al.
Pageof 15